Human intravenous immunoglobulin use for hematological immune-mediated disease in dogs
The aim of this study was to report survival rates and risk factors in dogs with immune-mediated hemolytic anemia (IMHA) and immune-mediated thrombocytopenia (ITP) treated with human IV immunoglobulin (hIVIG; Privigen). The authors hypothesized that hIVIG could be used as a salvage treatment to improve survival and reduce the requirement for ongoing blood transfusion therapy in IMHA and ITP patients.
Researchers conducted a retrospective cohort analysis between January 2006 and January 2022 that assessed the survival rates, risk factors and need for ongoing transfusion in dogs with IMHA and ITP treated with hIVIG compared with those not receiving hIVIG.
The team enrolled 52 client-owned dogs with IMHA or ITP, comprising 31 females (28 spayed and 3 entire) and 21 males (19 castrated and 2 entire). Miniature Schnauzers were the most common breed (5), with a further 24 different breeds identified.
Of 36 dogs that did not receive hIVIG, 29 (80%) survived and 7 (24%) died, and of 16 dogs administered hIVIG, 11 (69%) survived and 5 (31%) died (P = .56). No effect of PCV at admission or age on the risk of death was detected (OR, 1.00; 95% CI, 0.94 to 1.08; P = .89; and OR, 1.10; 95% CI, 0.85 to 1.47; P = .47, respectively).
This is the largest study to date of dogs with hematological immune-mediated disease treated with hIVIG. There was no difference in survival rates for dogs that received hIVIG versus those treated with standard immunosuppression.
In conclusion, the benefit of hIVIG as a salvage treatment appears limited.
Briannan-Kym Kane and Ristan Greer. “Human intravenous immunoglobulin use for hematological immune-mediated disease in dogs.” J Am Vet Med Assoc. 2023 Apr 18;1-7. doi: 10.2460/javma.23.01.0043.
Comments
Related Articles
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment